Neurology Alert – October 1, 2011
October 1, 2011
View Issues
-
Neuron-specific Enolase in Comatose Survivors of Cardiac Arrest After Therapeutic Hypothermia
Therapeutic hypothermia after cardiac arrest makes prediction of prognosis more difficult, and neuron-specific enolase measurements add an additional objective test to help determine outcome. -
Amyloid Mimics Chronic Inflammatory Demyelinating Polyneuropathy
Amyloidosis may present with the clinical and electrophysiologic features of chronic inflammatory demyelinating polyneuropathy. Nerve biopsy may be necessary to make an accurate diagnosis. -
Finding Order in Alzheimer's Biomarkers
Measurement of biomarkers, including Ab42 and tau protein in the CSF along with volumetric measurements of the hippocampus, may help in the diagnosis of early or presymptomatic Alzheimer's disease. -
Cortical Excitability Can Differentiate Migraine Types
Migraine patients show impairment in the processing of global visual features, compared with controls, both between and immediately after an attack. The pattern of ictal-interictal potential as noted on magnetoencephalography studies can characterize different migraine types. -
Sleep-Disordered Breathing is a Risk Factor for Dementia
Sleep-disordered breathing is a significant risk factor for cognitive decline and continuous positive airway pressure (CPAP) therapy may prevent or slow this process. -
Extended-Release Pramipexole in Early and Advanced Parkinson's Disease
Extended-release pramipexole is effective in both early and advanced Parkinson's disease, with a safety and tolerability profile similar to that of immediate-release pramipexole. -
Stroke Alert: A Review of Current Clinical Stroke Literature
It has been well recognized that a peak in stroke onset occurs during the early morning hours. This possible circadian periodicity is not well understood, and may in part represent stroke onset earlier during the night that goes unrecognized until the patient arouses. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.